View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2016	Mar. 09, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		57,655,714
Entity Public Float			$ 477,838,743

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 107,959	$ 94,094
Restricted cash	1,831
Short-term investments	11,160	7,225
Accounts receivable, net of allowance for doubtful accounts of $484 and $798	19,827	19,265
Inventories	11,799	13,242
Prepaid expenses	1,722	1,533
Other current assets	2,143	1,355
Total current assets	156,441	136,714
PROPERTY AND EQUIPMENT, net	20,033	20,083
INTANGIBLE ASSETS, net	10,337	12,591
GOODWILL	18,793	18,250
OTHER ASSETS	2,331	1,683
TOTAL ASSETS	207,935	189,321
CURRENT LIABILITIES:
Accounts payable	4,633	5,087
Deferred revenue	1,388	9,735
Accrued expenses	11,314	10,412
Total current liabilities	17,335	25,234
OTHER LIABILITIES	2,304	1,768
DEFERRED INCOME TAXES	2,446	2,883
COMMITMENTS AND CONTINGENCIES (Note 12)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 56,001 and 55,705 shares issued and outstanding	0	0
Additional paid-in capital	350,528	345,253
Accumulated other comprehensive loss	(14,220)	(15,639)
Accumulated deficit	(150,458)	(170,178)
Total stockholders' equity	185,850	159,436
Total liabilities and stockholders' equity	$ 207,935	$ 189,321

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 484	$ 798
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	56,001,000	55,705,000
Common stock, shares outstanding	56,001,000	55,705,000

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
NET REVENUES:
Product	$ 106,924	$ 104,458	$ 98,894
Other	21,274	15,261	7,570
Total revenue	128,198	119,719	106,464
COST OF PRODUCTS SOLD	40,171	39,426	39,840
Gross profit	88,027	80,293	66,624
OPERATING EXPENSES:
Research and development	9,754	11,654	12,058
Sales and marketing	29,652	35,088	41,118
General and administrative	28,356	25,493	23,750
Gain on contract termination settlement			(5,500)
Total operating expenses	67,762	72,235	71,426
Operating income (loss)	20,265	8,058	(4,802)
OTHER INCOME	58	774	531
Income (loss) before income taxes	20,323	8,832	(4,271)
INCOME TAX EXPENSE	603	665	343
NET INCOME (LOSS)	$ 19,720	$ 8,167	$ (4,614)
EARNINGS (LOSS) PER SHARE:
BASIC	$ 0.35	$ 0.14	$ (0.08)
DILUTED	$ 0.35	$ 0.14	$ (0.08)
SHARES USED IN COMPUTING EARNINGS (LOSS) PER SHARE:
BASIC	55,615	56,397	55,949
DILUTED	56,513	56,846	55,949

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
NET INCOME (LOSS)	$ 19,720	$ 8,167	$ (4,614)
OTHER COMPREHENSIVE INCOME (LOSS)
Currency translation adjustments	1,419	(7,791)	(4,051)
COMPREHENSIVE INCOME (LOSS)	$ 21,139	$ 376	$ (8,665)

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2013	$ 161,146		$ 338,674	$ (3,797)	$ (173,731)
Beginning Balance, Shares at Dec. 31, 2013		55,632
Common stock issued upon exercise of options	$ 1,115		1,115
Common stock issued upon exercise of options, Shares	249	249
Vesting of restricted stock	$ 0	$ 0	0	0	0
Vesting of restricted stock, Shares		428
Purchase and retirement of common shares	(639)		(639)
Purchase and retirement of common shares, Shares		(122)
Compensation cost for restricted stock	2,663		2,663
Compensation cost for stock option grants	3,081		3,081
NET INCOME (LOSS)	(4,614)				(4,614)
Currency translation adjustments	(4,051)			(4,051)
Ending Balance at Dec. 31, 2014	158,701		344,894	(7,848)	(178,345)
Ending Balance, Shares at Dec. 31, 2014		56,187
Common stock issued upon exercise of options	$ 404		404
Common stock issued upon exercise of options, Shares	74	74
Vesting of restricted stock	$ 0	$ 0	0	0	0
Vesting of restricted stock, Shares		354
Purchase and retirement of common shares	(6,090)		(6,090)
Purchase and retirement of common shares, Shares		(910)
Compensation cost for restricted stock	2,642		2,642
Compensation cost for stock option grants	3,403		3,403
NET INCOME (LOSS)	8,167				8,167
Currency translation adjustments	(7,791)			(7,791)
Ending Balance at Dec. 31, 2015	159,436		345,253	(15,639)	(170,178)
Ending Balance, Shares at Dec. 31, 2015		55,705
Common stock issued upon exercise of options	$ 2,656		2,656
Common stock issued upon exercise of options, Shares	405	405
Vesting of restricted stock	$ 0	$ 0	0	0	0
Vesting of restricted stock, Shares		446
Purchase and retirement of common shares	(3,444)		(3,444)
Purchase and retirement of common shares, Shares		(555)
Compensation cost for restricted stock	2,861		2,861
Compensation cost for stock option grants	2,691		2,691
Compensation cost for performance stock units	511		511
NET INCOME (LOSS)	19,720				19,720
Currency translation adjustments	1,419			1,419
Ending Balance at Dec. 31, 2016	$ 185,850		$ 350,528	$ (14,220)	$ (150,458)
Ending Balance, Shares at Dec. 31, 2016		56,001

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
OPERATING ACTIVITIES:
NET INCOME (LOSS)	$ 19,720	$ 8,167	$ (4,614)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation	6,063	6,045	5,744
Depreciation and amortization	5,687	5,696	6,307
Amortization of lease incentives	(78)	110
Amortization of debt issue costs	31
Unrealized foreign currency (gain) loss	122	367	(305)
Loss (gain) on sale of fixed assets	(28)	80
Deferred income taxes	(529)	48	294
Changes in assets and liabilities
Restricted cash	(1,831)
Accounts receivable	(576)	(3,739)	(3,381)
Inventories	1,476	2,348	(4,401)
Prepaid expenses and other assets	(652)	(1,415)	475
Accounts payable	46	(2,648)	2,194
Deferred revenue	(8,350)	1,706	6,943
Accrued expenses and other liabilities	1,666	(992)	(1,730)
Net cash provided by operating activities	22,767	15,773	7,526
INVESTING ACTIVITIES:
Purchases of short-term investments	(34,133)	(26,895)	(9,407)
Proceeds from maturities of short-term investments	30,421	23,934	4,432
Purchases of property and equipment	(4,353)	(3,744)	(3,005)
Net cash used in investing activities	(8,065)	(6,705)	(7,980)
FINANCING ACTIVITIES:
Payments for debt issue costs	(367)
Proceeds from exercise of stock options	2,656	404	1,115
Repurchase of common stock	(3,444)	(6,090)	(639)
Net cash (used in) provided by financing activities	(1,155)	(5,686)	476
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	318	(2,155)	(346)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	13,865	1,227	(324)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	94,094	92,867	93,191
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 107,959	$ 94,094	$ 92,867

The Company	12 Months Ended
The Company	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	1. THE COMPANY: We develop, manufacture, market and sell diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point-of-care, tests that are processed in a laboratory, and a rapid point-of-care HIV test approved for use in the domestic consumer retail or over-the-counter (“OTC”) market. We also manufacture and sell devices used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomic, personalized medicine, microbiome and animal genetic markets. Lastly, we manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. Our products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, commercial and industrial entities, retail pharmacies and mass merchandisers, and to consumers over the internet.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Principles of Consolidation and Basis of Presentation

The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiary, unless otherwise indicated.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding, and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Supplemental Cash Flow Information

In 2016, 2015 and 2014, we paid income taxes of $1,123, $719 and $31, respectively.

In 2016, 2015 and 2014, we recorded through the consolidated statements of operations an increase in our allowance for doubtful accounts of $40, $341 and $253, respectively. We had $369 in write-offs against the allowance for doubtful accounts in 2016. We had no material write-offs against the allowance for doubtful accounts in 2015 and 2014.

As of December 31, 2016, 2015 and 2014, we had accruals for purchases of property and equipment of $302, $1,256 and $217, respectively.

Short-Term Investments

We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

Accounts Receivable

Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.

Inventories

Inventories are stated at the lower of cost or market determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of our inventories are subject to expiration dating. We continually evaluate quantities on hand and the carrying value of our inventories to determine the need for reserves for excess and obsolete inventories, based primarily on the estimated forecast of product sales. When factors indicate that impairment has occurred, either a reserve is established against the inventories’ carrying value or the inventories are completely written off, as in the case of lapsing expiration dates. In addition to reserving for these items identified through specific identification procedures, we also reserve for unidentified scrap or spoilage under a fixed-formula methodology.

Property and Equipment

Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations.

Intangible Assets

Intangible assets consist of a customer list, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of one to fifteen years.

Impairment of Long-Lived Assets

We assess the recoverability of the our long-lived assets, which include property and equipment and intangible assets, by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, we measure the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets.

Goodwill

Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting unit with its aggregate carrying value, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with the respective carrying values.

We performed our annual impairment assessment as of July 31, 2016 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying value. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of December 31, 2016, we believe no indicators of impairment exist.

Revenue Recognition

We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for sales of our OraQuick^® In-Home HIV test to the retail trade, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

Our net revenues recorded on sales of the OraQuick^® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising, discounts, rebates, and chargebacks. The allowance for expected returns is an estimate established by management, based upon currently available information, and is adjusted to reflect known changes in the factors that impact this estimate. Other customer allowances are at contractual rates and are recorded as a reduction of gross revenue when recognized in our consolidated statements of operations.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

On June 10, 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie to co-promote our OraQuick^® HCV test in the United States. Pursuant to the agreement, we granted exclusive co-promotion rights for the OraQuick^® HCV test in certain markets to AbbVie and we agreed to develop, implement, administer and maintain a patient care database for the exclusive use of AbbVie. This patient care database was being used to compile patient information regarding new individuals who tested positive for HCV using our OraQuick^® HCV test. We also jointly agreed with AbbVie to co-promote our OraQuick^® HCV test in certain market segments.

Under the terms of this agreement, we were eligible to receive up to $75,000 in aggregate payments. We recognized this revenue ratably on a monthly basis over the term of the agreement, which was to terminate on December 31, 2019.

On June 30, 2016, we mutually agreed to terminate our agreement with AbbVie effective December 31, 2016. Following the termination of the agreement, AbbVie was relieved of its co-promotion obligations, including its obligation to detail the OraQuick^® HCV Rapid Test into physician offices, and has no further financial obligations to us. We are no longer obligated to compensate AbbVie for product detailing activities and are free to pursue arrangements with other pharmaceutical companies to market and promote our OraQuick^® HCV Rapid Antibody Test in the U.S. As a result of the shortened term, the remaining associated deferred revenue has been recognized ratably as other revenue over the last six months of 2016 as there are no substantive on-going obligations remaining beyond December 31, 2016. During 2016, 2015, and 2014, $18,951, $13,479 and $7,570, respectively, in exclusivity revenues were recognized and recorded as other revenue in our consolidated statements of operations.

On June 12, 2015, we were awarded a grant for up to $10,400 in total funding from the U.S. Department of Health and Human Services (“HHS”) Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority (“BARDA”) related to our OraQuick^® Ebola Rapid Antigen test. The three-year, multi-phased grant includes an initial commitment of $1,800 and options for up to an additional $8,600 to fund certain clinical and regulatory activities. In September 2015, BARDA exercised an option to provide $7,200 in additional funding for the development of our OraQuick^® Ebola Rapid Antigen test. Amounts related to this grant are recorded as other revenue in our consolidated statements of operations as the activities are being performed and the related costs are incurred. During 2016 and 2015, $1,707 and $1,783, respectively, were recognized in connection with this grant as other revenue in our consolidated statements of operations.

In August 2016, we were awarded a contract for up to $16,600 in total funding from BARDA related to our rapid Zika test. The six-year, multi-phased contract includes an initial commitment of $7,000 and options for up to an additional $9,600 to fund the evaluation of additional product enhancements, and clinical and regulatory activities. Funding received under this contract is recorded as other revenue in our consolidated statements of operations as the activities are being performed and the related costs are incurred. During 2016, $616 was recognized in connection with this grant as other revenue in our consolidated statements of operations.

Customer Sales Returns and Allowances

We do not grant product return rights to our customers for any product, except for our OraQuick^® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick^® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of December 31, 2016 and 2015, the reserve for sales returns and allowances was $217 and $310, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.

Deferred Revenue

We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of December 31, 2016 and 2015 includes customer prepayments of $1,388 and $784, respectively. Deferred revenue as of 2015 also includes $8,951 from AbbVie, which represents the excess of the exclusivity payments received from AbbVie over the amounts earned and recognized ratably in our consolidated statements of operations during that period.

Customer and Vendor Concentrations

One of our customers accounted for 15% of our accounts receivable as of December 31, 2016. We had no significant concentrations in accounts receivable as of December 31, 2015. One of our customers accounted for approximately 15% and 12% of our net consolidated revenues for the years ended December 31, 2016 and 2015, respectively. We had no significant concentrations in net consolidated revenues for the year ended December 31, 2014.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Research and Development

Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Research and development costs are charged to expense as incurred.

Advertising Expenses

Advertising costs are charged to expense as incurred. During 2016, 2015, and 2014, we incurred $626, $623, and $6,910, respectively, in advertising expenses.

Stock-Based Compensation

We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options or to issue restricted stock, or redeem performance based restricted stock units, we issue new shares rather than purchase shares on the open market.

Income Taxes

We follow the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, as well as operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates for the respective taxing jurisdiction that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

We assess the realizability of our net deferred tax assets on a quarterly basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, we reduce our net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of our net operating loss carryforwards.

Foreign Currency Translation

The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in our consolidated statements of operations in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions that are included in other income (expense) in our consolidated statements of operations were $(607), $1,005, and $273 for the years ended December 31, 2016, 2015, and 2014, respectively.

Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock, and performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.

The computations of basic and diluted earnings (loss) per share are as follows:


	Year ended December 31,
	2016		2015		2014
Net income (loss)	$	19,720	$	8,167	$	(4,614	)

Weighted average number of common shares outstanding:
Basic		55,615		56,397		55,949
Dilutive effect of stock options, restricted stock, and performance stock units		898		449		—

Diluted		56,513		56,846		55,949

Earnings (loss) per share:
Basic	$	0.35	$	0.14	$	(0.08	)

Diluted	$	0.35	$	0.14	$	(0.08	)

For the years ended December 31, 2016, 2015, and 2014, outstanding common stock options and unvested restricted stock representing 2,546, 4,314, and 6,447 shares, respectively, were excluded from the computation of diluted earnings (loss) per share as their inclusion would have been anti-dilutive.

Accumulated Other Comprehensive Loss

We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.

Our accumulated other comprehensive loss for 2016, 2015, and 2014 consisted of foreign currency translation adjustments.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $1,419, $(7,791) and $(4,051) currency translation adjustments recorded in 2016, 2015 and 2014, respectively, are largely the result of the translation of our Canadian operation’s financial statements into U.S. dollars.

Fair Value of Financial Instruments

As of December 31, 2016 and 2015, the carrying values of cash and cash equivalents, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1:

Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2:

Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3:

Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Included in cash and cash equivalents at December 31, 2016 and 2015, was $83,704 and $65,509 invested in government money market funds. These funds have investments in government securities and are Level I instruments.

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of December 31, 2016 and 2015 was $1,980 and $1,324, respectively, and was calculated using the quoted market price of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.

Our available-for-sale securities as of December 31, 2016 and 2015 consisted of guaranteed investment certificates with amortized cost and fair value of $11,160 and $7,225, respectively, and are measured as Level 1 instruments.

In 2016, we purchased certificates of deposit (“CD”) from a commercial bank. The CDs bear interest at an annual rate ranging from 0.18% to 0.31% and mature monthly through February 28, 2018. The carrying values of the CDs approximate their fair value. These CDs serve as collateral for certain standby letters of credit and are reported as restricted cash on the accompanying consolidated balance sheets. Also see Note 12 – Commitments and Contingencies.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09, Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, at which point we plan to adopt the standard.

The FASB allows two adoption methods under ASU 2014-09. We plan to adopt the standard using the “modified retrospective method.” Under that method, we will apply the rules to all contracts existing as of January 1, 2018, recognizing in beginning retained earnings an adjustment for the cumulative effective of the change and providing additional disclosures comparing results to previous accounting standards.

Upon initial evaluation, we believe the key changes in the standard that impact our revenue recognition relate to the allocation of the transaction price to performance obligations related to our device and lab services for drug testing. This revenue stream amounts to less than 1% of total consolidated revenues. We continue to evaluate the impact that the adoption of ASU 2014-09 will have on our consolidated financial statements and related disclosures, but do not anticipate the adoption to have a material impact on our financial results.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory, which requires an entity that uses the first-in, first-out method for inventory measurement to report inventory cost at the lower of cost and net realizable value versus the current measurement principle of lower of cost or market. The ASU requires prospective adoption for inventory measurements for fiscal years beginning after December 15, 2016. We are adopting ASU 2015-11 as of January 1, 2017. The adoption of this standard will not have a material impact on our consolidated financial statements and related disclosures.

In February 2016, the FASB issued ASU 2016-02, Leases, which requires entities to begin recording assets and liabilities from leases on the balance sheet. The new guidance will also require significant additional disclosures about the amount, timing and uncertainty of cash flows from leases. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018, using a modified retrospective approach. Early adoption is permitted. We are evaluating the effect that ASU 2016-02 may have on our consolidated financial statements and related disclosures. Our total lease commitments at December 31, 2016 are $2,001. Also see Note 12 – Commitments and Contingencies.

In March 2016, the FASB issued authoritative guidance under ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 provides for simplification of several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. We will adopt ASU 2016-09 on January 1, 2017. While we have a full valuation allowance against our net deferred tax assets, the adoption of this standard will not have a material impact on our consolidated financial statements and related disclosures. Should the full valuation allowance be reversed in future periods the adoption of this new guidance will introduce more volatility to our effective tax rate.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which provides guidance related to cash flows presentation and is effective for annual reporting periods beginning after December 15, 2017, subject to early adoption. The majority of the guidance in ASU 2016-15 is consistent with our current cash flow classifications and we do not expect the adoption of this standard will have a material impact on our consolidated financial statements.

Inventories

12 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Inventories

3. INVENTORIES:


	December 31,
	2016		2015
Raw materials	$	5,399	$	7,895
Work in process		1,034		333
Finished goods		5,366		5,014

	$	11,799	$	13,242

Property and Equipment

12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

Property and Equipment

4. PROPERTY AND EQUIPMENT:


	December 31,
	2016			2015
Land	$	1,118		$	1,118
Buildings and improvements		20,179			18,549
Machinery and equipment		22,764			21,263
Computer equipment and software		8,357			7,644
Furniture and fixtures		2,113			1,584
Construction in progress		1,569			2,938

		56,100			53,096
Less accumulated depreciation		(36,067	)		(33,013	)

	$	20,033		$	20,083

Depreciation expense was $3,149, $2,992, and $3,123 for 2016, 2015, and 2014, respectively.

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

5. GOODWILL AND OTHER INTANGIBLE ASSETS:

The changes in goodwill are as follows:


	December 31,
	2016		2015
Balance as of January 1	$	18,250	$	21,734
Change related to foreign currency translation		543		(3,484	)

Balance as of December 31	$	18,793	$	18,250

Intangible assets consist of the following:


			December 31, 2016
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	9,321	$	(4,830	)	$	4,491
Patents and product rights		10		5,400		(3,808	)		1,592
Acquired technology		7		7,240		(5,279	)		1,961
Tradename		15		3,573		(1,280	)		2,293

			$	25,534	$	(15,197	)	$	10,337


			December 31, 2015
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	9,051	$	(3,818	)	$	5,233
Patents and product rights		10		5,400		(3,358	)		2,042
Acquired technology		7		7,030		(4,172	)		2,858
Tradename		15		3,469		(1,011	)		2,458

			$	24,950	$	(12,359	)	$	12,591

Patents and products rights are made up of the following:


	December 31,
	2016			2015
HIV-related	$	900		$	900
HCV-related		4,500			4,500

		5,400			5,400
Less accumulated amortization		(3,808	)		(3,358	)

	$	1,592		$	2,042

Amortization expense for 2016, 2015, and 2014 was $2,538, $2,704, and $3,184, respectively.

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:


2017	$	2,538
2018		2,535
2019		1,570
2020		1,362
2021		1,118
Beyond		1,214

	$	10,337

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accrued Expenses

12 Months Ended

Dec. 31, 2016

Payables and Accruals [Abstract]

Accrued Expenses

6. ACCRUED EXPENSES:


	December 31,
	2016		2015
Payroll and related benefits	$	7,685	$	6,311
Professional Fees		982		1,014
Royalties		715		819
Other		1,932		2,268

	$	11,314	$	10,412

Credit Facility	12 Months Ended
Credit Facility	Dec. 31, 2016
Debt Disclosure [Abstract]
Credit Facility	7. CREDIT FACILITY: On September 30, 2016, we entered into a credit agreement (the “Credit Agreement”) with a commercial bank. The Credit Agreement provides for revolving extensions of credit in an initial aggregate amount of up to $10,000 (inclusive of a letter of credit sub-facility of $2,500), with an option to request, prior to the second anniversary of the closing date, that the lender, at its election, provide up to $5,000 of additional revolving commitments. Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets. There were no borrowings under the facility from September 30, 2016 through December 31, 2016. Borrowings under the Credit Agreement are subject to compliance with borrowing base limitations tied to eligibility of accounts receivable. Interest under the Credit Agreement is payable at the London Interbank Offered Rate for one, two, three or six-month loans, as selected by the Company, plus 2.50% per year. The Credit Agreement is subject to an unused line fee of 0.375% per year on the unused portion of the commitment under the Credit Agreement during the revolving period. The maturity date of the Credit Agreement is September 30, 2019. In connection with the Credit Agreement, under certain circumstances, we must comply with a minimum fixed charge coverage ratio of 1.10 to 1.00, measured as of the last day of each fiscal month and for the twelve-fiscal month period ending on such date. As of December 31, 2016, we were in compliance with all applicable covenants in the Credit Agreement.

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

8. INCOME TAXES:

Income (loss) before income tax expense (benefit) consists of the following:


	Years Ended December 31,
	2016		2015		2014
United States	$	18,492	$	5,302	$	(6,156	)
Canada		1,831		3,530		1,885

	$	20,323	$	8,832	$	(4,271	)

The components of the income tax expense (benefit) are as follows:


	Years Ended December 31,
	2016			2015			2014
Current
Federal	$	—		$	—		$	—
State		250			—			—
Canada		882			617			49

		1,132			617			49

Deferred
Federal		6,508			1,511			(2,248	)
State		569			311			(827	)
Canada		(529	)		48			294

		6,548			1,870			(2,781	)
(Decrease) increase in valuation allowance		(7,077	)		(1,822	)		3,075

		(529	)		48			294

Total income tax expense	$	603		$	665		$	343

For the years ended December 31, 2016, 2015, and 2014 we recorded foreign income tax expense of $353, $665, and $343, respectively.

A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2016, 2015, and 2014 is as follows:


	2016			2015			2014
Statutory U.S. federal income tax rate		34.0	%		34.0	%		34.0	%
Tax effect of Canadian items		(4.9	)		(13.1	)		28.0
State income taxes, net of federal benefit		2.0			1.5			13.5
Nondeductible expenses and other		6.7			5.7			(11.5	)
Change in valuation allowance, federal and state		(34.8	)		(20.6	)		(72.0	)

Effective tax rate		3.0	%		7.5	%		(8.0	)%

Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes, and net operating loss and tax credit carryforwards. Significant components of our deferred tax assets (liabilities) as of December 31, 2016 and 2015 are as follows:


	2016			2015
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	17,673		$	21,985
Inventories		1,680			1,725
Capitalized research and development costs		4,711			4,803
Accruals and reserves currently not deductible		3,282			5,782
Acquired intangible assets		(2,268	)		(2,725	)
Depreciation and amortization		(212	)		(367	)
Stock-based compensation		6,110			6,371
Investment tax credit carryforward		(134	)		(92	)
Research and development tax credit carryforward		1,885			1,885

Net deferred tax asset		32,727			39,367
Valuation allowance		(35,173	)		(42,250	)

Net deferred tax liability	$	(2,446	)	$	(2,883	)

In assessing the realizability of our net deferred tax asset, we consider all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent upon several factors, including the generation of sufficient taxable income prior to the expiration of the NOL carryforwards. In 2008, we established a full valuation allowance against our U.S. deferred tax asset, and management believes the full valuation allowance is still appropriate as of December 31, 2016 and 2015 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal income tax benefit was recorded for the years ended December 31, 2016, 2015, or 2014. The valuation allowance decreased by $7,077 in 2016 due to the use of net operating losses to offset U.S. taxable income.

Our Federal NOL carryforwards expire as follows:


Year of Expiration	NOLs
2021 - 2025	$	9,494
2026 - 2030		14,285
2031 - 2036		27,077

	$	50,856

The Tax Reform Act of 1986 contains provisions that limit the annual amount of NOLs available to be used in any given year in the event of a significant change in ownership. Our ability to use our federal and state NOL carryforwards to offset future federal income tax obligations could be limited by changes in the ownership of our stock. Internal Revenue Code (“IRC”) Section 382 contains provisions that limit the amount of federal and state NOL carryforwards that can be used in any given year in the event of specified occurrences, including significant ownership changes. The Company does not believe, however, that there is a Section 382 limitation that will impair our future ability to utilize NOLs to offset our future taxable income. The Company continues to review ownership changes on an annual basis and we do not believe we have had a subsequent ownership change that would impact the NOLs.

As of December 31, 2016, our gross unrecognized tax benefits totaled $2,084, and based upon the valuation allowance for our U.S. operations, the recognition of any tax benefit would not impact our effective tax rate. We record interest and penalties related to unrecognized tax benefits as a component of income tax expense. Interest and penalties were immaterial in 2016, 2015 and 2014. As a result of our net operating loss carryforward position, we are subject to audit by the Internal Revenue Service since our inception, as well as by several state jurisdictions for the years ended September 30, 1998 through December 31, 2016.

A reconciliation of our unrecognized tax benefits is as follows:


	2016			2015			2014
Balance as of January 1	$	2,088		$	2,073		$	2,051
Additions for tax positions of prior periods		—			22			25
Reductions for tax positions of prior periods		(4	)		(7	)		(3	)

Balance as of December 31	$	2,084		$	2,088		$	2,073

Stockholders' Equity

12 Months Ended

Dec. 31, 2016

Equity [Abstract]

Stockholders' Equity

9. STOCKHOLDERS’ EQUITY:

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards.

As of December 31, 2016, 2,568 shares were available for future grants under the Stock Plan.

Under the terms of the Stock Plan, nonqualified options may be granted to eligible employees, including our officers at a price not less than 75 percent of the fair market value of a share of common stock on the date of grant. The option term and vesting schedule of such awards may be either unlimited or have a specified period in which to vest and be exercised. To date, options generally have been granted with ten-year exercise periods and an exercise price not less than the fair market value on the date of grant. Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:


	Years Ended December 31,
	2016			2015			2014
Black-Scholes Option Valuation Assumptions
Risk-free interest rate⁽¹⁾		1.76	%		1.49	%		2.13	%
Expected dividend yield		—			—			—
Expected stock price volatility⁽²⁾		46	%		51	%		50	%
Expected life of stock options (in years)⁽²⁾		7			7			7

⁽¹⁾	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options.

⁽²⁾	Based upon historical experience.

The weighted-average grant date fair value of stock options granted during the years ended December 31, 2016, 2015 and 2014 was $2.91, $4.86 and $3.03, respectively.

Compensation expense recognized in the financial statements related to stock options was as follows:


	Years Ended December 31,
	2016			2015			2014
Total compensation cost during the year	$	2,691		$	3,403		$	3,081
Amounts capitalized into inventory during the year		(270	)		(153	)		(148	)
Amounts recognized in cost of products sold for amounts previously capitalized		212			153			128

Amounts charged against income	$	2,633		$	3,403		$	3,061

The aggregate intrinsic value of options exercised during the years ended December 31, 2016, 2015, and 2014 (the amount by which the market price of the stock on the date of exercise exceeded the exercise price) was $763, $329, and $901, respectively.

The following table summarizes the stock option activity under the Stock Plan:


	Options			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding on January 1, 2014		5,271		$	7.54
Granted		1,202			5.77
Exercised		(249	)		5.09
Expired		(388	)		8.38
Forfeited		(96	)		7.43

Outstanding on December 31, 2014		5,740			7.22
Granted		773			9.28
Exercised		(74	)		5.46
Expired		(163	)		8.55
Forfeited		(60	)		8.07

Outstanding on December 31, 2015		6,216			7.46
Granted		347			6.00
Exercised		(405	)		6.57
Expired		(479	)		9.17
Forfeited		(223	)		7.31

Outstanding on December 31, 2016		5,456		$	7.28		5.6	$	10,267

Vested or expected to vest as of December 31, 2016		5,426		$	7.29		5.6	$	10,207

Exercisable on December 31, 2016		4,538		$	7.33		5.1	$	8,519

As of December 31, 2016, there was $2,965 of unrecognized compensation expense related to unvested option awards that is expected to be recognized over a weighted-average period of 2.0 years.

Net cash proceeds from the exercise of stock options were $2,656, $404 and $1,115 for the years ended December 31, 2016, 2015, and 2014, respectively. As a result of our net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises for these periods.

The following table summarizes information about stock options outstanding as of December 31, 2016:


Options outstanding							Options exercisable
Range of exercise prices	Number Outstanding		Weighted- Average Remaining Contractual Term (in years)		Weighted- Average Exercise Price Per Share		Number Exercisable		Weighted- Average Exercise Price Per Share
$2.55 - $5.19		597		6.5	$	4.41		597	$	4.41
$5.37 - $5.47		234		9.0		5.37		3		5.42
$5.71		948		6.7		5.71		706		5.71
$5.72 - $6.37		221		5.3		5.97		194		5.96
$6.63		633		3.9		6.63		633		6.63
$6.67 - $6.99		34		7.3		6.92		20		6.93
$7.05		726		5.7		7.05		703		7.05
$7.28 - $8.28		631		2.4		7.93		597		7.96
$8.33 - $9.30		127		4.4		8.66		88		8.81
$9.31 - $12.14		1,305		6.2		10.32		997		10.64

		5,456		5.6	$	7.28		4,538	$	7.33

The Stock Plan also permits us to grant restricted shares of our common stock to eligible employees, including officers, and our outside directors. Generally, these shares are nontransferable until vested and are subject to vesting requirements and/or forfeiture, as determined by our Compensation Committee or Board of Directors. The market value of these shares at the date of grant is recognized on a straight-line basis over the period during which the restrictions lapse. Compensation cost of $2,861, $2,642 and $2,663 related to restricted shares was recognized during the years ended December 31, 2016, 2015, and 2014, respectively.

The following table summarizes restricted stock award activity under the Stock Plan:


	Shares			Weighted-Average Grant Date Fair Value
Issued and unvested, January 1, 2014		653		$	7.15
Granted		506			5.82
Vested		(428	)		6.65
Forfeited		(24	)		7.38

Issued and unvested, December 31, 2014		707			6.50
Granted		362			8.25
Vested		(354	)		6.94
Forfeited		(18	)		8.01

Issued and unvested, December 31, 2015		697			7.14
Granted		632			5.63
Vested		(446	)		6.65
Forfeited		(133	)		6.43

Issued and unvested, December 31, 2016		750		$	6.28

Issued and expected to vest, December 31, 2016		750		$	6.28

As of December 31, 2016, there was $2,607 of unrecognized compensation expense related to unvested restricted stock awards that is expected to be recognized over a weighted average period of 1.7 years.

In connection with the vesting of restricted shares and exercise of stock options during the years ended December 31, 2016, 2015 and 2014, we purchased and immediately retired 132, 133 and 122 shares with aggregate values of $784, $1,164 and $639, respectively, in satisfaction of minimum tax withholding and exercise obligations.

Commencing in 2016, we granted to certain executives performance-based restricted stock units (“PSUs”). Vesting of these PSUs is dependent upon achievement of performance-based metrics during a one-year or three-year period, from the date of grant. Assuming achievement of each performance-based metrics, the executive must also remain in our service for three years, commencing with the grant date. Performance during the one-year period will be based on a one-year earnings per share target. Upon achievement of the one-year target, the PSUs will then vest three years from grant date. Performance during the three-year period will be based on achievement of a three-year compound annual growth rate for consolidated product revenues. Upon achievement of the three-year target, the corresponding PSUs will vest in full. PSUs are converted into shares of our common stock once vested. Upon grant of the PSUs, we recognize compensation expense related to these awards based on assumptions as to what percentage of each target will be achieved. The Company evaluates these target assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate. The 2016 one-year earnings per share target was met during the year ended December 31, 2016 and as such, one-third of the related compensation expense was recognized during the year.

As of December 31, 2016, there were 456 PSUs issued and unvested at a weighted-average grant date fair value of $5.46. Compensation cost of $511 related to the PSUs was recognized during the year ended December 31, 2016.

Share Repurchase Program

On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. During the years ended December 31, 2016 and 2015, we purchased and retired 423 and 777 shares of common stock at an average price of $6.29 and $6.34 per share for a total cost of $2,660 and $4,926, respectively. No shares were purchased and retired in 2014.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Termination Settlement	12 Months Ended
Termination Settlement	Dec. 31, 2016
Unusual or Infrequent Items, or Both [Abstract]
Termination Settlement	10. TERMINATION SETTLEMENT: On November 21, 2013, we terminated our assay development and commercialization agreement with Roche Diagnostics (“Roche”). Pursuant to this termination agreement, Roche paid us $8,300, which was recorded as a reduction of operating expense on our consolidated statements of operations for the quarter ended December 31, 2013. Roche agreed to provide certain transitional product support services to us and to supply certain of the assays developed under the collaboration on a transitional basis for up to five years following the termination. We had the right to stop the supply of assays prior to the end of this five-year period and to receive an additional payment from Roche of up to $5,500 depending on how early in that five-year period the supply obligation was ended. During the second quarter of 2014, we issued our final purchase order for assays previously developed under the terminated agreement and as such, recorded $5,500 as a reduction of operating expense in our consolidated statements of operations.

Business Segment Information

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Business Segment Information

11. BUSINESS SEGMENT INFORMATION:

We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of diagnostic products, specimen collection devices and medical devices; and our molecular collection systems or “DNAG” business, which primarily consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, retail pharmacies and mass merchandisers, and to consumers over the internet. OSUR also derives other revenues, including exclusivity payments for co-promotion rights and other licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of customers engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, microbiome, and animal genetic testing. DNAG products are also sold into the academic research market, which consists of research laboratories, universities and hospitals.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.

The following table summarizes operating segment information for the years ended December 31, 2016, 2015, and 2014, and asset information as of December 31, 2016 and 2015:


	Years Ended December 31,
	2016		2015		2014
Net revenues:
OSUR	$	95,984	$	89,795	$	82,686
DNAG		32,214		29,924		23,778

Total	$	128,198	$	119,719	$	106,464

Operating income (loss):
OSUR	$	15,606	$	3,558	$	(8,324	)
DNAG		4,659		4,500		3,522

Total	$	20,265	$	8,058	$	(4,802	)

Depreciation and amortization:
OSUR	$	2,720	$	3,015	$	3,254
DNAG		2,967		2,681		3,053

Total	$	5,687	$	5,696	$	6,307

Capital expenditures:
OSUR	$	2,145	$	1,645	$	2,170
DNAG		2,208		2,099		835

Total	$	4,353	$	3,744	$	3,005


	December 31,
	2016		2015
Total assets:
OSUR	$	151,719	$	137,082
DNAG		56,216		52,239

Total	$	207,935	$	189,321

Our products are sold principally in the United States and Europe.

The following table represents total net revenues by geographic area, based on the location of the customer:


	Years Ended December 31,
	2016		2015		2014
United States	$	99,758	$	96,522	$	82,256
Europe		11,646		13,535		13,913
Other regions		16,794		9,662		10,295

	$	128,198	$	119,719	$	106,464

The following table represents total long-lived assets by geographic area:


	December 31,
	2016		2015
United States	$	15,737	$	15,660
Canada		4,286		4,415
Other regions		10		8

	$	20,033	$	20,083

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

12. COMMITMENTS AND CONTINGENCIES:

Sublicense Agreement

In June 2004, we entered into a sublicense agreement with a third party pursuant to which we have been granted a limited, worldwide, non-exclusive sublicense to certain HIV-2 patents held by such party. Under the terms of this sublicense agreement, we are obligated to pay royalties based on a percentage of our net sales of certain products, which incorporate the technology covered by the licensed patents. Royalties are expensed as an element of cost of goods sold. Future minimum payments under this agreement are as follows:


2017	$	500
2018		292

	$	792

Royalties from our commercial sale of products covered by the sublicense can be credited against these minimum royalty obligations.

Leases

We lease office space for our Canadian subsidiary and domestic warehouse facilities under operating lease agreements. Future payments required under these non-cancelable leases are as follows:


2017	$	339
2018		334
2019		317
2020		341
2021		335
Thereafter		335

	$	2,001

Rent expense for 2016, 2015 and 2014 was $715, $481, and $401, respectively.

Purchase Commitments

As of December 31, 2016, we had outstanding non-cancelable purchase commitments related to inventory, supplies, capital expenditures, and other goods or services as follows:


2017	$	7,418
2018		3,088
2019		383
2020		383

	$	11,272

Certain commitments under supply agreements are cancellable within a specified number of days of written notice to the supplier.

Employment Agreements

Under terms of employment agreements with certain employees, which extend through 2019, we are required to pay each individual a base salary for continuing employment with us. The agreements require payments totaling $1,775, $1,275, and $317 in 2017, 2018, and 2019, respectively.

Standby Letters of Credit

In 2016, we established two standby letters of credit in the aggregate amount of $1,800, naming an international customer as the beneficiary. These letters of credit were required as a performance guarantee of our obligations under our contract with that customer and are collateralized by certificates of deposit maintained at a commercial bank.

Litigation

From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.

In May 2015, our subsidiary DNAG filed a complaint in the United States District Court for the District of Delaware against Ancestry.com DNA LLC (“Ancestry”) relating to the manufacture and sale by Ancestry of its oral fluid DNA collection device (the “Ancestry Device”). Ancestry previously purchased DNAG’s patented oral fluid DNA collection devices. The complaint alleged that the manufacture and sale by Ancestry of the Ancestry Device infringes U.S. Patent No. 8,221,381 B2, which is owned by DNAG. In addition, the complaint alleged that Ancestry has breached the terms of agreements under which Ancestry previously purchased DNAG products. The complaint also included an action to quiet title to the Ancestry Device and related patent applications. DNAG requested the court to grant injunctive relief and damages.

On October 20, 2015, Ancestry filed with the United States Patent and Trademark Office (“USPTO”) a Petition for Inter Partes Review (“IPR”) of some, but not all, claims of U.S. Patent No. 8,221,381 B2. On April 8, 2016, the USPTO instituted an IPR of some, but not all, of the claims raised in Ancestry’s petition. On June 3, 2016, Ancestry filed a second Petition for IPR of some, but not all, of the claims of U.S. Patent No. 8,221,381 B2.

In July 2015, DNAG filed a complaint in the United States District Court for the District of Delaware against Spectrum DNA, Spectrum Solutions L.L.C. and Spectrum Packaging L.L.C. (collectively “Spectrum”) relating to the manufacture and sale by Spectrum of an oral fluid DNA collection device (the “Spectrum Device”). The Spectrum Device is the same as the Ancestry device mentioned above and Spectrum is the manufacturer of the Ancestry Device for Ancestry. The complaint alleged that the manufacture and sale by Spectrum of the Spectrum Device infringes U.S. patent number 8,221,381 B-2, which is owned by DNAG. DNAG requested the court to grant injunctive relief and damages. Spectrum filed a motion to dismiss this lawsuit on the grounds that the Delaware District Court lacked jurisdiction over Spectrum. The Court granted Spectrum’s motion to dismiss for lack of personal jurisdiction.

On June 20, 2016, DNAG filed a complaint in the United States District Court for the Southern District of California against Spectrum relating to the manufacture and sale of the Spectrum Device. The complaint alleged that the manufacture and sale by Spectrum of the Spectrum Device infringes U.S. Patent No. 9,207,164, which is owned by DNAG. DNAG requested the court to grant injunctive relief and damages. On June 21, 2016, DNAG filed a motion for preliminary injunction. On July 21, 2016, Spectrum filed a motion to stay the case pending resolution by the PTO of a Petition for IPR of U.S. Patent No. 9,207,164, which was filed by Ancestry in July 2016. On October 6, 2016, the Court issued an order denying DNAG’s motion for preliminary injunction and on October 7, 2016, the Court issued an order staying the case pending resolution of the IPR of U.S. Patent No. 9,207,164.

Effective February 6, 2017, DNAG settled the foregoing litigation with Ancestry and Spectrum. Under a Settlement and License Agreement executed by the parties, Ancestry agreed to pay DNAG a settlement fee of $12,500. This settlement amount will be recorded as a separate line item and a reduction of our operating expenses in our statement of income in 2017. In addition, DNAG granted Ancestry a royalty-bearing, non-exclusive, worldwide license to certain patents and patent applications related to the collection of DNA in human saliva. The license granted to Ancestry is limited to saliva DNA collection kits sold or used as part of Ancestry’s genetic testing service offerings and does not cover the sale or use of collection kits outside of Ancestry’s business. The Settlement and License Agreement also provides DNAG with a royalty-free, non-exclusive license to patents related to Ancestry’s existing saliva DNA collection kit and certain modifications thereto.

The parties have each agreed to a mutual release of claims and other provisions typical for settlement agreements of this type. Pursuant to the terms of the Settlement and License Agreement, the pending federal lawsuits in the District of Delaware and the Southern District of California have been dismissed and the IPR proceedings before the USPTO involving the DNAG patents asserted in the litigation have been terminated.

Retirement Plans	12 Months Ended
Retirement Plans	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Retirement Plans	13. RETIREMENT PLANS: Substantially all of our U.S. employees are eligible to participate in the OraSure Technologies, Inc. 401(k) Plan (the “401(k) Plan”). The 401(k) Plan permits voluntary employee contributions to be excluded from an employee’s current taxable income under provisions of Internal Revenue Code Section 401(k) and the regulations thereunder. The 401(k) Plan also provides for us to match employee contributions up to $4 per year. We contributed $619, $587, and $565 to the 401(k) Plan, net of forfeitures, in 2016, 2015, and 2014, respectively. In addition to our 401(k) plan, we offer a nonqualified deferred compensation plan to permit eligible highly compensated employees of the Company to defer receipt and taxation of their compensation each year. We also may make discretionary contributions to the accounts of the participating employees in any amount either in cash or stock. Participants in the plan may not purchase OraSure stock as an investment vehicle. As of December 31, 2016 and 2015, the value of the assets associated with this plan was $1,980 and $1,324, respectively, and is included in other assets in our consolidated balance sheet. Our obligation related to the deferred compensation plan is included in other liabilities in our consolidated balance sheet. As of December 31, 2016 and 2015, our total obligation under this plan was $1,980 and $1,324, respectively. Substantially all regular full-time Canadian employees are eligible to participate in the DNA Genotek Registered Retirement Savings Plan (the “RRSP”). The RRSP permits voluntary employee contributions to be excluded from an employee’s current taxable income and receive tax preferred treatment with Revenue Canada. The RRSP also provides for DNAG to match employee contributions up to $2 per year. We contributed $134, $134, and $136 to the RRSP in 2016, 2015, and 2014, respectively.

Quarterly Data

12 Months Ended

Dec. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Quarterly Data

14. QUARTERLY DATA (Unaudited):

The following tables summarize the quarterly results of operations for each of the quarters in 2016 and 2015. These quarterly results are unaudited, but in the opinion of management, have been prepared on the same basis as our audited financial information and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the information set forth herein.


	2016 Results
	Three months ended
	March 31, 2016			June 30, 2016			September 30, 2016			December 31, 2016
Net revenues	$	29,089		$	31,359		$	32,251	⁽¹⁾	$	35,499	⁽¹⁾
Costs and expenses		26,390			27,010			26,107			28,426

Operating income		2,699			4,349			6,144			7,073
Other income (expense), net		(192	)		(340	)		498			92

Income before income taxes		2,507			4,009			6,642			7,165
Income tax expense (benefit)		61			173			400			(31	)

Net income	$	2,446		$	3,836		$	6,242		$	7,196

Earnings per share
Basic	$	0.04		$	0.07		$	0.11		$	0.13

Diluted	$	0.04		$	0.07		$	0.11		$	0.13


	2015 Results
	Three months ended
	March 31, 2015			June 30, 2015			September 30, 2015		December 31, 2015
Net revenues	$	27,088		$	30,388		$	29,861	$	32,382
Costs and expenses		27,379			27,667			28,325		28,290

Operating income (loss)		(291	)		2,721			1,536		4,092
Other income (expense), net		409			(95	)		81		379

Income before income taxes		118			2,626			1,617		4,471
Income tax expense (benefit)		5			658			147		(145	)

Net income	$	113		$	1,968		$	1,470	$	4,616

Earnings per share
Basic	$	0.00		$	0.03		$	0.03	$	0.08

Diluted	$	0.00		$	0.03		$	0.03	$	0.08

⁽¹⁾	Revenues in the last six months of 2016 include additional $5,436 of exclusivity payments recognized in other revenues as a result of the early termination of our HCV co-promotion agreement with AbbVie.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Principles of Consolidation and Basis of Presentation

Use of Estimates

Use of Estimates

Supplemental Cash Flow Information

Supplemental Cash Flow Information

In 2016, 2015 and 2014, we paid income taxes of $1,123, $719 and $31, respectively.

As of December 31, 2016, 2015 and 2014, we had accruals for purchases of property and equipment of $302, $1,256 and $217, respectively.

Short-Term Investments

Short-Term Investments

Accounts Receivable

Accounts Receivable

Inventories

Inventories

Property and Equipment

Property and Equipment

Intangible Assets

Intangible Assets

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Goodwill

Goodwill

Revenue Recognition

Revenue Recognition

Customer Sales Returns and Allowances

Customer Sales Returns and Allowances

Deferred Revenue

Deferred Revenue

Customer and Vendor Concentrations

Customer and Vendor Concentrations

Research and Development

Research and Development

Advertising Expenses

Advertising Expenses

Advertising costs are charged to expense as incurred. During 2016, 2015, and 2014, we incurred $626, $623, and $6,910, respectively, in advertising expenses.

Stock-Based Compensation

Stock-Based Compensation

Income Taxes

Income Taxes

Foreign Currency Translation

Foreign Currency Translation

Earnings (Loss) Per Share

Earnings (Loss) Per Share

The computations of basic and diluted earnings (loss) per share are as follows:


	Year ended December 31,
	2016		2015		2014
Net income (loss)	$	19,720	$	8,167	$	(4,614	)

Weighted average number of common shares outstanding:
Basic		55,615		56,397		55,949
Dilutive effect of stock options, restricted stock, and performance stock units		898		449		—

Diluted		56,513		56,846		55,949

Earnings (loss) per share:
Basic	$	0.35	$	0.14	$	(0.08	)

Diluted	$	0.35	$	0.14	$	(0.08	)

Accumulated Other Comprehensive Loss

Accumulated Other Comprehensive Loss

Our accumulated other comprehensive loss for 2016, 2015, and 2014 consisted of foreign currency translation adjustments.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Level 1:

Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2:

Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3:

Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Computations of Basic and Diluted Earnings (Loss) Per Share

The computations of basic and diluted earnings (loss) per share are as follows:


	Year ended December 31,
	2016		2015		2014
Net income (loss)	$	19,720	$	8,167	$	(4,614	)

Weighted average number of common shares outstanding:
Basic		55,615		56,397		55,949
Dilutive effect of stock options, restricted stock, and performance stock units		898		449		—

Diluted		56,513		56,846		55,949

Earnings (loss) per share:
Basic	$	0.35	$	0.14	$	(0.08	)

Diluted	$	0.35	$	0.14	$	(0.08	)

Inventories (Tables)

12 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Schedule of Inventories


	December 31,
	2016		2015
Raw materials	$	5,399	$	7,895
Work in process		1,034		333
Finished goods		5,366		5,014

	$	11,799	$	13,242

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment


	December 31,
	2016			2015
Land	$	1,118		$	1,118
Buildings and improvements		20,179			18,549
Machinery and equipment		22,764			21,263
Computer equipment and software		8,357			7,644
Furniture and fixtures		2,113			1,584
Construction in progress		1,569			2,938

		56,100			53,096
Less accumulated depreciation		(36,067	)		(33,013	)

	$	20,033		$	20,083

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Changes in Goodwill

The changes in goodwill are as follows:


	December 31,
	2016		2015
Balance as of January 1	$	18,250	$	21,734
Change related to foreign currency translation		543		(3,484	)

Balance as of December 31	$	18,793	$	18,250

Summary of Intangible Assets

Intangible assets consist of the following:


			December 31, 2016
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	9,321	$	(4,830	)	$	4,491
Patents and product rights		10		5,400		(3,808	)		1,592
Acquired technology		7		7,240		(5,279	)		1,961
Tradename		15		3,573		(1,280	)		2,293

			$	25,534	$	(15,197	)	$	10,337


			December 31, 2015
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	9,051	$	(3,818	)	$	5,233
Patents and product rights		10		5,400		(3,358	)		2,042
Acquired technology		7		7,030		(4,172	)		2,858
Tradename		15		3,469		(1,011	)		2,458

			$	24,950	$	(12,359	)	$	12,591

Summary of Patents and Products Rights

Patents and products rights are made up of the following:


	December 31,
	2016			2015
HIV-related	$	900		$	900
HCV-related		4,500			4,500

		5,400			5,400
Less accumulated amortization		(3,808	)		(3,358	)

	$	1,592		$	2,042

Summary of Amortization Expense

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:


2017	$	2,538
2018		2,535
2019		1,570
2020		1,362
2021		1,118
Beyond		1,214

	$	10,337

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2016

Payables and Accruals [Abstract]

Schedule of Accrued Expenses


	December 31,
	2016		2015
Payroll and related benefits	$	7,685	$	6,311
Professional Fees		982		1,014
Royalties		715		819
Other		1,932		2,268

	$	11,314	$	10,412

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Schedule of Income (Loss) Before Income Tax Expense (Benefit)

Income (loss) before income tax expense (benefit) consists of the following:


	Years Ended December 31,
	2016		2015		2014
United States	$	18,492	$	5,302	$	(6,156	)
Canada		1,831		3,530		1,885

	$	20,323	$	8,832	$	(4,271	)

Components of Income Tax Expense (Benefit)

The components of the income tax expense (benefit) are as follows:


	Years Ended December 31,
	2016			2015			2014
Current
Federal	$	—		$	—		$	—
State		250			—			—
Canada		882			617			49

		1,132			617			49

Deferred
Federal		6,508			1,511			(2,248	)
State		569			311			(827	)
Canada		(529	)		48			294

		6,548			1,870			(2,781	)
(Decrease) increase in valuation allowance		(7,077	)		(1,822	)		3,075

		(529	)		48			294

Total income tax expense	$	603		$	665		$	343

Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate

A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2016, 2015, and 2014 is as follows:


	2016			2015			2014
Statutory U.S. federal income tax rate		34.0	%		34.0	%		34.0	%
Tax effect of Canadian items		(4.9	)		(13.1	)		28.0
State income taxes, net of federal benefit		2.0			1.5			13.5
Nondeductible expenses and other		6.7			5.7			(11.5	)
Change in valuation allowance, federal and state		(34.8	)		(20.6	)		(72.0	)

Effective tax rate		3.0	%		7.5	%		(8.0	)%

Components of Total Deferred Tax Assets (Liabilities)

Significant components of our deferred tax assets (liabilities) as of December 31, 2016 and 2015 are as follows:


	2016			2015
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	17,673		$	21,985
Inventories		1,680			1,725
Capitalized research and development costs		4,711			4,803
Accruals and reserves currently not deductible		3,282			5,782
Acquired intangible assets		(2,268	)		(2,725	)
Depreciation and amortization		(212	)		(367	)
Stock-based compensation		6,110			6,371
Investment tax credit carryforward		(134	)		(92	)
Research and development tax credit carryforward		1,885			1,885

Net deferred tax asset		32,727			39,367
Valuation allowance		(35,173	)		(42,250	)

Net deferred tax liability	$	(2,446	)	$	(2,883	)

Expiry Details of Federal Net Operating Losses Carryforwards

Our Federal NOL carryforwards expire as follows:


Year of Expiration	NOLs
2021 - 2025	$	9,494
2026 - 2030		14,285
2031 - 2036		27,077

	$	50,856

Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits

A reconciliation of our unrecognized tax benefits is as follows:


	2016			2015			2014
Balance as of January 1	$	2,088		$	2,073		$	2,051
Additions for tax positions of prior periods		—			22			25
Reductions for tax positions of prior periods		(4	)		(7	)		(3	)

Balance as of December 31	$	2,084		$	2,088		$	2,073

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2016

Equity [Abstract]

Weighted-Average Assumptions for Fair Value Measurement

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:


	Years Ended December 31,
	2016			2015			2014
Black-Scholes Option Valuation Assumptions
Risk-free interest rate⁽¹⁾		1.76	%		1.49	%		2.13	%
Expected dividend yield		—			—			—
Expected stock price volatility⁽²⁾		46	%		51	%		50	%
Expected life of stock options (in years)⁽²⁾		7			7			7

⁽¹⁾	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options.

⁽²⁾	Based upon historical experience.

Schedule of Compensation Expense Recognized in Financial Statements Related to Stock Options

Compensation expense recognized in the financial statements related to stock options was as follows:


	Years Ended December 31,
	2016			2015			2014
Total compensation cost during the year	$	2,691		$	3,403		$	3,081
Amounts capitalized into inventory during the year		(270	)		(153	)		(148	)
Amounts recognized in cost of products sold for amounts previously capitalized		212			153			128

Amounts charged against income	$	2,633		$	3,403		$	3,061

Summary of Company's Stock Option Activity

The following table summarizes the stock option activity under the Stock Plan:


	Options			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding on January 1, 2014		5,271		$	7.54
Granted		1,202			5.77
Exercised		(249	)		5.09
Expired		(388	)		8.38
Forfeited		(96	)		7.43

Outstanding on December 31, 2014		5,740			7.22
Granted		773			9.28
Exercised		(74	)		5.46
Expired		(163	)		8.55
Forfeited		(60	)		8.07

Outstanding on December 31, 2015		6,216			7.46
Granted		347			6.00
Exercised		(405	)		6.57
Expired		(479	)		9.17
Forfeited		(223	)		7.31

Outstanding on December 31, 2016		5,456		$	7.28		5.6	$	10,267

Vested or expected to vest as of December 31, 2016		5,426		$	7.29		5.6	$	10,207

Exercisable on December 31, 2016		4,538		$	7.33		5.1	$	8,519

Schedule of Currently Outstanding and Exercisable Stock Options

The following table summarizes information about stock options outstanding as of December 31, 2016:


Options outstanding							Options exercisable
Range of exercise prices	Number Outstanding		Weighted- Average Remaining Contractual Term (in years)		Weighted- Average Exercise Price Per Share		Number Exercisable		Weighted- Average Exercise Price Per Share
$2.55 - $5.19		597		6.5	$	4.41		597	$	4.41
$5.37 - $5.47		234		9.0		5.37		3		5.42
$5.71		948		6.7		5.71		706		5.71
$5.72 - $6.37		221		5.3		5.97		194		5.96
$6.63		633		3.9		6.63		633		6.63
$6.67 - $6.99		34		7.3		6.92		20		6.93
$7.05		726		5.7		7.05		703		7.05
$7.28 - $8.28		631		2.4		7.93		597		7.96
$8.33 - $9.30		127		4.4		8.66		88		8.81
$9.31 - $12.14		1,305		6.2		10.32		997		10.64

		5,456		5.6	$	7.28		4,538	$	7.33

Summary of Restricted Stock Award Activity under Stock Plan

The following table summarizes restricted stock award activity under the Stock Plan:


	Shares			Weighted-Average Grant Date Fair Value
Issued and unvested, January 1, 2014		653		$	7.15
Granted		506			5.82
Vested		(428	)		6.65
Forfeited		(24	)		7.38

Issued and unvested, December 31, 2014		707			6.50
Granted		362			8.25
Vested		(354	)		6.94
Forfeited		(18	)		8.01

Issued and unvested, December 31, 2015		697			7.14
Granted		632			5.63
Vested		(446	)		6.65
Forfeited		(133	)		6.43

Issued and unvested, December 31, 2016		750		$	6.28

Issued and expected to vest, December 31, 2016		750		$	6.28

Business Segment Information (Tables)

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Summary of Operating Segment and Asset Information

The following table summarizes operating segment information for the years ended December 31, 2016, 2015, and 2014, and asset information as of December 31, 2016 and 2015:


	Years Ended December 31,
	2016		2015		2014
Net revenues:
OSUR	$	95,984	$	89,795	$	82,686
DNAG		32,214		29,924		23,778

Total	$	128,198	$	119,719	$	106,464

Operating income (loss):
OSUR	$	15,606	$	3,558	$	(8,324	)
DNAG		4,659		4,500		3,522

Total	$	20,265	$	8,058	$	(4,802	)

Depreciation and amortization:
OSUR	$	2,720	$	3,015	$	3,254
DNAG		2,967		2,681		3,053

Total	$	5,687	$	5,696	$	6,307

Capital expenditures:
OSUR	$	2,145	$	1,645	$	2,170
DNAG		2,208		2,099		835

Total	$	4,353	$	3,744	$	3,005


	December 31,
	2016		2015
Total assets:
OSUR	$	151,719	$	137,082
DNAG		56,216		52,239

Total	$	207,935	$	189,321

Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area

The following table represents total net revenues by geographic area, based on the location of the customer:


	Years Ended December 31,
	2016		2015		2014
United States	$	99,758	$	96,522	$	82,256
Europe		11,646		13,535		13,913
Other regions		16,794		9,662		10,295

	$	128,198	$	119,719	$	106,464

The following table represents total long-lived assets by geographic area:


	December 31,
	2016		2015
United States	$	15,737	$	15,660
Canada		4,286		4,415
Other regions		10		8

	$	20,033	$	20,083

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule for Future Minimum Payments under Sublicense Agreement

Future minimum payments under this agreement are as follows:


2017	$	500
2018		292

	$	792

Schedule for Future Minimum Lease Payments under Operating Lease Agreements

Future payments required under these non-cancelable leases are as follows:


2017	$	339
2018		334
2019		317
2020		341
2021		335
Thereafter		335

	$	2,001

Schedule of Outstanding Non-cancelable Purchase Commitments

As of December 31, 2016, we had outstanding non-cancelable purchase commitments related to inventory, supplies, capital expenditures, and other goods or services as follows:


2017	$	7,418
2018		3,088
2019		383
2020		383

	$	11,272

Quarterly Data (Tables)

12 Months Ended

Dec. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Summary of Quarterly Results of Operations


	2016 Results
	Three months ended
	March 31, 2016			June 30, 2016			September 30, 2016			December 31, 2016
Net revenues	$	29,089		$	31,359		$	32,251	⁽¹⁾	$	35,499	⁽¹⁾
Costs and expenses		26,390			27,010			26,107			28,426

Operating income		2,699			4,349			6,144			7,073
Other income (expense), net		(192	)		(340	)		498			92

Income before income taxes		2,507			4,009			6,642			7,165
Income tax expense (benefit)		61			173			400			(31	)

Net income	$	2,446		$	3,836		$	6,242		$	7,196

Earnings per share
Basic	$	0.04		$	0.07		$	0.11		$	0.13

Diluted	$	0.04		$	0.07		$	0.11		$	0.13


	2015 Results
	Three months ended
	March 31, 2015			June 30, 2015			September 30, 2015		December 31, 2015
Net revenues	$	27,088		$	30,388		$	29,861	$	32,382
Costs and expenses		27,379			27,667			28,325		28,290

Operating income (loss)		(291	)		2,721			1,536		4,092
Other income (expense), net		409			(95	)		81		379

Income before income taxes		118			2,626			1,617		4,471
Income tax expense (benefit)		5			658			147		(145	)

Net income	$	113		$	1,968		$	1,470	$	4,616

Earnings per share
Basic	$	0.00		$	0.03		$	0.03	$	0.08

Diluted	$	0.00		$	0.03		$	0.03	$	0.08

⁽¹⁾	Revenues in the last six months of 2016 include additional $5,436 of exclusivity payments recognized in other revenues as a result of the early termination of our HCV co-promotion agreement with AbbVie.

Summary of Significant Accounting Policies - Additional Information (Detail) shares in Thousands					1 Months Ended		12 Months Ended
	Dec. 31, 2016 USD ($) Supplier	Dec. 31, 2015 USD ($)	Jun. 12, 2015 USD ($)	Dec. 31, 2014 USD ($)	Aug. 31, 2016 USD ($)	Sep. 30, 2015 USD ($)	Dec. 31, 2016 USD ($) Supplier shares	Dec. 31, 2015 USD ($) shares	Dec. 31, 2014 USD ($) shares	Dec. 31, 2013 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income taxes paid							$ 1,123,000	$ 719,000	$ 31,000
Increase or decrease in allowance for doubtful accounts							40,000	341,000	253,000
Write-offs against allowance for doubtful accounts							$ 369,000	0	0
Accruals for purchases of property and equipment	$ 302,000	$ 1,256,000		$ 217,000
Expiration date of rights agreement							Dec. 31, 2019
Revenue recognized							$ 18,951,000	13,479,000	7,570,000
Maximum value of grant revenue from clinical and regulatory activities			$ 10,400,000		$ 16,600,000
Initial grant revenue from clinical and regulatory activities			1,800,000		7,000,000
Remaining grant revenue from clinical and regulatory activities			$ 8,600,000		$ 9,600,000
Period of grant			3 years		6 years
Additional contract revenue from clinical and regulatory activities						$ 7,200,000
Contract revenues from clinical and regulatory activities							616,000
Reserve for sales return and allowances							217,000	310,000
Deferred revenue	1,388,000	9,735,000					1,388,000	9,735,000
Advertising expenses							626,000	623,000	6,910,000
Net foreign exchange gains (losses)							(607,000)	1,005,000	273,000
Accumulated foreign currency adjustments included in other comprehensive loss amounted	1,419,000	(7,791,000)		(4,051,000)			1,419,000	(7,791,000)	(4,051,000)
Cash and cash equivalents	107,959,000	94,094,000		$ 92,867,000			107,959,000	94,094,000	$ 92,867,000	$ 93,191,000
Fair value of plan assets	1,980,000	1,324,000					1,980,000	1,324,000
Available-for-sale securities, fair values	11,160,000	7,225,000					11,160,000	7,225,000
Total lease commitments	2,001,000						2,001,000
Money Market Fund [Member] \| Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	83,704,000	$ 65,509,000					$ 83,704,000	$ 65,509,000
Common Stock Options and Unvested Restricted Stock [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation \| shares							2,546	4,314	6,447
Accounts Receivable [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk		0.00%
Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk									0.00%
Up Front Payment Arrangement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue	$ 1,388,000	$ 784,000					$ 1,388,000	$ 784,000
AbbVie [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue		8,951,000						$ 8,951,000
AbbVie [Member] \| Collaborative Arrangement Co-promotion [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Expiration date of rights agreement							Dec. 31, 2016
Customer One [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk	15.00%
Customer One [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk							15.00%	12.00%
Guaranteed Investment Certificates [Member] \| Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Available-for-sale securities, amortized cost	$ 11,160,000	11,160,000					$ 11,160,000	$ 11,160,000
Available-for-sale securities, fair values	$ 7,225,000	$ 7,225,000					7,225,000	7,225,000
Other [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Contract revenues from clinical and regulatory activities							$ 1,707,000	$ 1,783,000
Certificates of Deposit [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Certificates of deposit maturity date							Feb. 28, 2018
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets							15 years
Maximum [Member] \| Collaborative Arrangement Co-promotion [Member] \| OraQuick HCV [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Payments received for sale of exclusive rights							$ 75,000,000
Maximum [Member] \| Net Consolidated Revenue [Member] \| Revenue from Rights Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk							1.00%
Maximum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets							40 years
Maximum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets							10 years
Maximum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets							10 years
Maximum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets							10 years
Maximum [Member] \| Certificates of Deposit [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest rate on certificates of deposit							0.31%
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets							1 year
Minimum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets							20 years
Minimum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets							2 years
Minimum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets							2 years
Minimum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets							2 years
Minimum [Member] \| Certificates of Deposit [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest rate on certificates of deposit							0.18%
DNA Genotek [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of third-party suppliers to manufacture DNAG's products \| Supplier	2						2

Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share [Abstract]
NET INCOME (LOSS)	$ 7,196	$ 6,242	$ 3,836	$ 2,446	$ 4,616	$ 1,470	$ 1,968	$ 113	$ 19,720	$ 8,167	$ (4,614)
Weighted average number of common shares outstanding:
BASIC									55,615	56,397	55,949
Dilutive effect of stock options, restricted stock, and performance stock units									898	449
Diluted									56,513	56,846	55,949
BASIC	$ 0.13	$ 0.11	$ 0.07	$ 0.04	$ 0.08	$ 0.03	$ 0.03	$ 0.00	$ 0.35	$ 0.14	$ (0.08)
DILUTED	$ 0.13	$ 0.11	$ 0.07	$ 0.04	$ 0.08	$ 0.03	$ 0.03	$ 0.00	$ 0.35	$ 0.14	$ (0.08)

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventory, Net [Abstract]
Raw materials	$ 5,399	$ 7,895
Work in process	1,034	333
Finished goods	5,366	5,014
Inventories	$ 11,799	$ 13,242

Property and Equipment - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$ 56,100	$ 53,096
Less accumulated depreciation	(36,067)	(33,013)
Property plant and equipment Net	20,033	20,083
Land [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	1,118	1,118
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	20,179	18,549
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	22,764	21,263
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	8,357	7,644
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	2,113	1,584
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$ 1,569	$ 2,938

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 3,149	$ 2,992	$ 3,123

Goodwill and Other Intangible Assets - Schedule of Changes in Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Goodwill [Roll Forward]
Beginning Balance	$ 18,250	$ 21,734
Change related to foreign currency translation	543	(3,484)
Ending Balance	$ 18,793	$ 18,250

Goodwill and Other Intangible Assets - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 25,534	$ 24,950
Intangible Assets, Accumulated Amortization	(15,197)	(12,359)
Intangible Assets, Net	$ 10,337	$ 12,591
Customer List [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Intangible Assets, Gross	$ 9,321	$ 9,051
Intangible Assets, Accumulated Amortization	(4,830)	(3,818)
Intangible Assets, Net	$ 4,491	$ 5,233
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Intangible Assets, Gross	$ 5,400	$ 5,400
Intangible Assets, Accumulated Amortization	(3,808)	(3,358)
Intangible Assets, Net	$ 1,592	$ 2,042
Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	7 years	7 years
Intangible Assets, Gross	$ 7,240	$ 7,030
Intangible Assets, Accumulated Amortization	(5,279)	(4,172)
Intangible Assets, Net	$ 1,961	$ 2,858
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	15 years	15 years
Intangible Assets, Gross	$ 3,573	$ 3,469
Intangible Assets, Accumulated Amortization	(1,280)	(1,011)
Intangible Assets, Net	$ 2,293	$ 2,458

Goodwill and Other Intangible Assets - Summary of Patents and Products Rights (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	$ 25,534	$ 24,950
Less accumulated amortization	(15,197)	(12,359)
Patent and products right, Net	10,337	12,591
HIV-Related [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	900	900
HCV-Related [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	4,500	4,500
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	5,400	5,400
Less accumulated amortization	(3,808)	(3,358)
Patent and products right, Net	$ 1,592	$ 2,042

Goodwill and Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 2,538	$ 2,704	$ 3,184

Goodwill and Other Intangible Assets - Summary of Amortization Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2017	$ 2,538
2018	2,535
2019	1,570
2020	1,362
2021	1,118
Beyond	1,214
Intangible Assets, Net	$ 10,337	$ 12,591

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accrued Liabilities, Current [Abstract]
Payroll and related benefits	$ 7,685	$ 6,311
Professional fees	982	1,014
Royalties	715	819
Other	1,932	2,268
Accrued Expenses, Total	$ 11,314	$ 10,412

Credit Facility - Additional Information (Detail)	12 Months Ended
Credit Facility - Additional Information (Detail)	Dec. 31, 2016 USD ($)
Line of Credit Facility [Line Items]
Current borrowing capacity	$ 10,000,000
Line of credit facility, collateral	Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets.
Borrowings	$ 0
Unused capacity commitment fee	0.375%
Maturity date of credit facility	Sep. 30, 2019
Maximum [Member]
Line of Credit Facility [Line Items]
Additional revolving commitments	$ 5,000,000
Letter of Credit [Member]
Line of Credit Facility [Line Items]
Current borrowing capacity	$ 2,500,000
Line of Credit [Member]
Line of Credit Facility [Line Items]
Line of credit, interest rate	2.50%
Credit facility, description of variable rate basis	LIBOR
Minimum fixed charge coverage ratio	110.00%

Income Taxes - Schedule of Income (Loss) Before Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract]
United States									$ 18,492	$ 5,302	$ (6,156)
Canada									1,831	3,530	1,885
Income (loss) before income taxes	$ 7,165	$ 6,642	$ 4,009	$ 2,507	$ 4,471	$ 1,617	$ 2,626	$ 118	$ 20,323	$ 8,832	$ (4,271)

Income Taxes - Components of Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current
Federal									$ 0	$ 0	$ 0
State									250
Canada									882	617	49
Total current income tax expense (benefit)									1,132	617	49
Deferred
Federal									6,508	1,511	(2,248)
State									569	311	(827)
Canada									(529)	48	294
Total deferred income tax expense (benefit)									6,548	1,870	(2,781)
(Decrease) increase in valuation allowance									(7,077)	(1,822)	3,075
Deferred income taxes									(529)	48	294
Total income tax expense	$ (31)	$ 400	$ 173	$ 61	$ (145)	$ 147	$ 658	$ 5	$ 603	$ 665	$ 343

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Foreign income tax expense	$ 353	$ 665	$ 343
U.S. federal income tax benefits	0	0	0
Decrease in valuation allowance	(7,077)	(1,822)	3,075
Gross unrecognized tax benefits	$ 2,084	$ 2,088	$ 2,073	$ 2,051

Income Taxes - Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory U.S. federal income tax rate	34.00%	34.00%	34.00%
Tax effect of Canadian items	(4.90%)	(13.10%)	28.00%
State income taxes, net of federal benefit	2.00%	1.50%	13.50%
Nondeductible expenses and other	6.70%	5.70%	(11.50%)
Change in valuation allowance, federal and state	(34.80%)	(20.60%)	(72.00%)
Effective tax rate	3.00%	7.50%	(8.00%)

Income Taxes - Components of Total Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets (liabilities):
Net operating loss carryforwards	$ 17,673	$ 21,985
Inventories	1,680	1,725
Capitalized research and development costs	4,711	4,803
Accruals and reserves currently not deductible	3,282	5,782
Acquired intangible assets	(2,268)	(2,725)
Depreciation and amortization	(212)	(367)
Stock-based compensation	6,110	6,371
Investment tax credit carryforward	(134)	(92)
Research and development tax credit carryforward	1,885	1,885
Net deferred tax asset	32,727	39,367
Valuation allowance	(35,173)	(42,250)
Net deferred tax liability	$ (2,446)	$ (2,883)

Income Taxes - Expiry Details of Federal Net Operating Losses Carryforwards (Detail) $ in Thousands	Dec. 31, 2016 USD ($)
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 50,856
2021-2025 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	9,494
2026-2030 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	14,285
2031-2036 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 27,077

Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance as of January 1	$ 2,088	$ 2,073	$ 2,051
Additions for tax positions of prior periods		22	25
Reductions for tax positions of prior periods	(4)	(7)	(3)
Balance as of December 31	$ 2,084	$ 2,088	$ 2,073

Stockholders' Equity - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants under the Stock Plan	2,568,000
Proceeds from exercise of stock options	$ 2,656,000	$ 404,000	$ 1,115,000
Income tax benefit realized from stock option exercises during period	0	0	0
Total compensation cost	6,063,000	6,045,000	5,744,000
Amount share repurchase program of common shares					$ 25,000,000
Total cost of common stock purchased and retired	$ 3,444,000	$ 6,090,000	$ 639,000
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	423	777	0
Average price of common stock	$ 6.29	$ 6.34
Total cost of common stock purchased and retired	$ 2,660,000	$ 4,926,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of the fair market value of a share granted as Stock plan price	75.00%
Granted exercise periods	10 years
Vesting period	4 years
Vesting of Options	Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.
Weighted-average grant date fair value of stock options granted	$ 2.91	$ 4.86	$ 3.03
Aggregate intrinsic value of options exercised	$ 763,000	$ 329,000	$ 901,000
Unrecognized compensation expense related to unvested option awards	$ 2,965,000
Expected weighted-average period for recognition of compensation expense related to unvested awards	2 years
Proceeds from exercise of stock options	$ 2,656,000	404,000	1,115,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognition of compensation expense related to unvested awards	1 year 8 months 12 days
Total compensation cost	$ 2,861,000	$ 2,642,000	$ 2,663,000
Unrecognized compensation expense related to unvested restricted stock awards	$ 2,607,000
Vesting of restricted shares and exercise of stock options, withholding and exercise obligations	132,000	133,000	122,000
Restricted shares of common stock and stock options, aggregate values	$ 784,000	$ 1,164,000	$ 639,000
Shares, issued and unvested	750,000	697,000	707,000	653,000
Weighted-average grant date fair value, issued and unvested	$ 6.28	$ 7.14	$ 6.50	$ 7.15
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 511,000
Shares, issued and unvested	456,000
Weighted-average grant date fair value, issued and unvested	$ 5.46

Stockholders' Equity - Weighted-Average Assumptions for Fair Value Measurement (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate	1.76%	1.49%	2.13%
Expected dividend yield	0.00%	0.00%	0.00%
Expected stock price volatility	46.00%	51.00%	50.00%
Expected life of stock options (in years)	7 years	7 years	7 years

Stockholders' Equity - Schedule of Compensation Expense Recognized in Financial Statements Related to Stock Options (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Total compensation cost during the year	$ 2,691	$ 3,403	$ 3,081
Amounts capitalized into inventory during the year	(270)	(153)	(148)
Amounts recognized in cost of products sold for amounts previously capitalized	212	153	128
Amounts charged against income	$ 2,633	$ 3,403	$ 3,061

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options, Outstanding, Beginning Balance	6,216	5,740	5,271
Options, Granted	347	773	1,202
Options, Exercised	(405)	(74)	(249)
Options, Expired	(479)	(163)	(388)
Options, Forfeited	(223)	(60)	(96)
Options, Outstanding, Ending Balance	5,456	6,216	5,740
Weighted-Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 7.46	$ 7.22	$ 7.54
Options, Vested or expected to vest	5,426
Weighted-Average Exercise Price Per Share, Granted	$ 6.00	9.28	5.77
Options, Exercisable	4,538
Weighted-Average Exercise Price Per Share, Exercised	$ 6.57	5.46	5.09
Weighted-Average Exercise Price Per Share, Expired	9.17	8.55	8.38
Weighted-Average Exercise Price Per Share, Forfeited	7.31	8.07	7.43
Weighted-Average Exercise Price Per Share, Outstanding, Ending Balance	7.28	$ 7.46	$ 7.22
Weighted-Average Exercise Price Per Share, Vested or expected to vest	7.29
Weighted-Average Exercise Price Per Share, Exercisable	$ 7.33
Weighted-Average Remaining Contractual Term, Outstanding	5 years 7 months 6 days
Weighted-Average Remaining Contractual Term, Vested or expected to vest	5 years 7 months 6 days
Weighted-Average Remaining Contractual Term, Exercisable	5 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding	$ 10,267
Aggregate Intrinsic Value, Vested or expected to vest	10,207
Aggregate Intrinsic Value, Exercisable	$ 8,519

Stockholders' Equity - Schedule of Currently Outstanding and Exercisable Stock Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2016 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding, Options outstanding \| shares	5,456
Weighted-Average Remaining Contractual Term (in years), Options outstanding	5 years 7 months 6 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 7.28
Number Exercisable, Options exercisable \| shares	4,538
Weighted-Average Exercise Price Per Share, Options exercisable	$ 7.33
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	2.55
Range of exercise prices, Upper Range Limit	$ 5.19
Number Outstanding, Options outstanding \| shares	597
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 6 months
Weighted-Average Exercise Price Per Share, Options outstanding	$ 4.41
Number Exercisable, Options exercisable \| shares	597
Weighted-Average Exercise Price Per Share, Options exercisable	$ 4.41
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	5.37
Range of exercise prices, Upper Range Limit	$ 5.47
Number Outstanding, Options outstanding \| shares	234
Weighted-Average Remaining Contractual Term (in years), Options outstanding	9 years
Weighted-Average Exercise Price Per Share, Options outstanding	$ 5.37
Number Exercisable, Options exercisable \| shares	3
Weighted-Average Exercise Price Per Share, Options exercisable	$ 5.42
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 5.71
Number Outstanding, Options outstanding \| shares	948
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 8 months 12 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 5.71
Number Exercisable, Options exercisable \| shares	706
Weighted-Average Exercise Price Per Share, Options exercisable	$ 5.71
Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	5.72
Range of exercise prices, Upper Range Limit	$ 6.37
Number Outstanding, Options outstanding \| shares	221
Weighted-Average Remaining Contractual Term (in years), Options outstanding	5 years 3 months 18 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 5.97
Number Exercisable, Options exercisable \| shares	194
Weighted-Average Exercise Price Per Share, Options exercisable	$ 5.96
Range Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 6.63
Number Outstanding, Options outstanding \| shares	633
Weighted-Average Remaining Contractual Term (in years), Options outstanding	3 years 10 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 6.63
Number Exercisable, Options exercisable \| shares	633
Weighted-Average Exercise Price Per Share, Options exercisable	$ 6.63
Range Six [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	6.67
Range of exercise prices, Upper Range Limit	$ 6.99
Number Outstanding, Options outstanding \| shares	34
Weighted-Average Remaining Contractual Term (in years), Options outstanding	7 years 3 months 18 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 6.92
Number Exercisable, Options exercisable \| shares	20
Weighted-Average Exercise Price Per Share, Options exercisable	$ 6.93
Range Seven [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 7.05
Number Outstanding, Options outstanding \| shares	726
Weighted-Average Remaining Contractual Term (in years), Options outstanding	5 years 8 months 12 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 7.05
Number Exercisable, Options exercisable \| shares	703
Weighted-Average Exercise Price Per Share, Options exercisable	$ 7.05
Range Eight [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	7.28
Range of exercise prices, Upper Range Limit	$ 8.28
Number Outstanding, Options outstanding \| shares	631
Weighted-Average Remaining Contractual Term (in years), Options outstanding	2 years 4 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 7.93
Number Exercisable, Options exercisable \| shares	597
Weighted-Average Exercise Price Per Share, Options exercisable	$ 7.96
Range Nine [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	8.33
Range of exercise prices, Upper Range Limit	$ 9.30
Number Outstanding, Options outstanding \| shares	127
Weighted-Average Remaining Contractual Term (in years), Options outstanding	4 years 4 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 8.66
Number Exercisable, Options exercisable \| shares	88
Weighted-Average Exercise Price Per Share, Options exercisable	$ 8.81
Range Ten [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	9.31
Range of exercise prices, Upper Range Limit	$ 12.14
Number Outstanding, Options outstanding \| shares	1,305
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 2 months 12 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 10.32
Number Exercisable, Options exercisable \| shares	997
Weighted-Average Exercise Price Per Share, Options exercisable	$ 10.64

Stockholders' Equity - Summary of Restricted Stock Award Activity Under Stock Plan (Detail) - Restricted Stock [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	697	707	653
Shares, Granted	632	362	506
Shares, Vested	(446)	(354)	(428)
Shares, Forfeited	(133)	(18)	(24)
Shares, Issued and unvested, Ending Balance	750	697	707
Weighted-Average Grant Date Fair Value, Issued and unvested, Beginning Balance	$ 7.14	$ 6.50	$ 7.15
Shares, Issued and expected to vest	750
Weighted-Average Grant Date Fair Value, Granted	$ 5.63	8.25	5.82
Weighted-Average Grant Date Fair Value, Vested	6.65	6.94	6.65
Weighted-Average Grant Date Fair Value, Forfeited	6.43	8.01	7.38
Weighted-Average Grant Date Fair Value, Issued and unvested, Ending Balance	6.28	$ 7.14	$ 6.50
Weighted-Average Grant Date Fair Value, Issued and expected to vest	$ 6.28

Termination Settlement - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2016	Dec. 31, 2014
Unusual or Infrequent Item, or Both [Line Items]
Gain on contract termination settlement	$ 5,500,000	$ 8,300,000		$ 5,500,000
Termination date			Nov. 21, 2013
Notice period after termination of contract			5 years
Maximum [Member]
Unusual or Infrequent Item, or Both [Line Items]
Additional payment received relating to termination of contract			$ 5,500,000

Business Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Net revenues	$ 35,499	$ 32,251	$ 31,359	$ 29,089	$ 32,382	$ 29,861	$ 30,388	$ 27,088	$ 128,198	$ 119,719	$ 106,464
Operating income (loss)	7,073	$ 6,144	$ 4,349	$ 2,699	4,092	$ 1,536	$ 2,721	$ (291)	20,265	8,058	(4,802)
Depreciation and amortization									5,687	5,696	6,307
Capital expenditures									4,353	3,744	3,005
Total assets	207,935				189,321				207,935	189,321
OSUR [Member]
Segment Reporting Information [Line Items]
Net revenues									95,984	89,795	82,686
Operating income (loss)									15,606	3,558	(8,324)
Depreciation and amortization									2,720	3,015	3,254
Capital expenditures									2,145	1,645	2,170
Total assets	151,719				137,082				151,719	137,082
DNAG [Member]
Segment Reporting Information [Line Items]
Net revenues									32,214	29,924	23,778
Operating income (loss)									4,659	4,500	3,522
Depreciation and amortization									2,967	2,681	3,053
Capital expenditures									2,208	2,099	$ 835
Total assets	$ 56,216				$ 52,239				$ 56,216	$ 52,239

Business Segment Information - Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	$ 35,499	$ 32,251	$ 31,359	$ 29,089	$ 32,382	$ 29,861	$ 30,388	$ 27,088	$ 128,198	$ 119,719	$ 106,464
Long-lived assets	20,033				20,083				20,033	20,083
United States [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues									99,758	96,522	82,256
Long-lived assets	15,737				15,660				15,737	15,660
Europe [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues									11,646	13,535	13,913
Other Regions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues									16,794	9,662	$ 10,295
Long-lived assets	10				8				10	8
Canada [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 4,286				$ 4,415				$ 4,286	$ 4,415

Commitments and Contingencies - Schedule for Future Minimum Payments under Sublicense Agreement (Detail) $ in Thousands	Dec. 31, 2016 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2017	$ 500
2018	292
Total	$ 792

Commitments and Contingencies - Schedule for Future Minimum Lease Payments under Operating Lease Agreements (Detail) $ in Thousands	Dec. 31, 2016 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2017	$ 339
2018	334
2019	317
2020	341
2021	335
Thereafter	335
Total	$ 2,001

Commitments and Contingencies - Additional Information (Detail) $ in Thousands		12 Months Ended
	Feb. 06, 2017 USD ($)	Dec. 31, 2016 USD ($) Debt_Instruments	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Contractual Obligation Fiscal Year Maturity [Line Items]
Rent expense		$ 715	$ 481	$ 401
Required salary payment as per agreements with employees, next year		500
Required salary payment as per agreements with employees, second year		292
DNA Genotek [Member] \| Subsequent Event [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Settlement fee	$ 12,500
Employment Agreements [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Required salary payment as per agreements with employees, next year		1,775
Required salary payment as per agreements with employees, second year		1,275
Required salary payment as per agreements with employees, third year		317
Standby Letters of Credit [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Standby letters of credit		$ 1,800
Debt instrument, number of letters of credit \| Debt_Instruments		2

Commitments and Contingencies - Schedule of Outstanding Non-cancelable Purchase Commitments (Detail) $ in Thousands	Dec. 31, 2016 USD ($)
Purchase Obligation, Fiscal Year Maturity [Abstract]
2017	$ 7,418
2018	3,088
2019	383
2020	383
Total	$ 11,272

Retirement Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	$ 4,000
Contributed to plan, net of forfeitures	619,000	$ 587,000	$ 565,000
Value of the assets associated with the plan	1,980,000	1,324,000
Total obligation under plan	1,980,000	1,324,000
RRSP [Member] \| DNA Genotek [Member]
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	2,000
Contributed to plan, net of forfeitures	$ 134,000	$ 134,000	$ 136,000

Quarterly Data - Summary of Quarterly Results of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Net revenues	$ 35,499	$ 32,251	$ 31,359	$ 29,089	$ 32,382	$ 29,861	$ 30,388	$ 27,088	$ 128,198	$ 119,719	$ 106,464
Costs and expenses	28,426	26,107	27,010	26,390	28,290	28,325	27,667	27,379
Operating income (loss)	7,073	6,144	4,349	2,699	4,092	1,536	2,721	(291)	20,265	8,058	(4,802)
Other income (expense), net	92	498	(340)	(192)	379	81	(95)	409	58	774	531
Income before income taxes	7,165	6,642	4,009	2,507	4,471	1,617	2,626	118	20,323	8,832	(4,271)
Income tax expense (benefit)	(31)	400	173	61	(145)	147	658	5	603	665	343
Net income	$ 7,196	$ 6,242	$ 3,836	$ 2,446	$ 4,616	$ 1,470	$ 1,968	$ 113	$ 19,720	$ 8,167	$ (4,614)
Earnings per share
BASIC	$ 0.13	$ 0.11	$ 0.07	$ 0.04	$ 0.08	$ 0.03	$ 0.03	$ 0.00	$ 0.35	$ 0.14	$ (0.08)
DILUTED	$ 0.13	$ 0.11	$ 0.07	$ 0.04	$ 0.08	$ 0.03	$ 0.03	$ 0.00	$ 0.35	$ 0.14	$ (0.08)

Quarterly Data - Summary of Quarterly Results of Operations (Parenthetical) (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($)
AbbVie [Member]
Payments recognized in other revenues	$ 5,436